Summit Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 14, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	13,979	13,561	13,167	1,831	897	264
Market Cap Growth	-19.77%	3.00%	618.96%	104.13%	240.18%	-32.05%
Enterprise Value	14,005	12,865	12,758	1,748	1,066	193.63
Last Close Price	18.01	17.49	17.85	2.61	4.25	2.69
PE Ratio	-	-12.15	-57.58	-2.64	-10.37	-4.01
PB Ratio	26.71	20.58	33.87	23.57	7.08	3.17
P/TBV Ratio	24.97	19.85	32.99	20.82	6.49	4.25
P/FCF Ratio	-	-41.91	-92.56	-23.82	-21.26	-3.62
P/OCF Ratio	-	-41.99	-92.65	-23.86	-21.58	-3.63
EV/EBITDA Ratio	-	11.75	65.07	-4.05	-15.05	-2.31
EV/EBIT Ratio	-	11.76	65.10	-4.05	-14.78	-2.25
EV/FCF Ratio	-	-39.76	-89.69	-22.74	-25.25	-2.66
Debt / Equity Ratio	0.03	0.03	0.01	1.33	4.08	0.02
Debt / EBITDA Ratio	0.02	0.02	0.04	-0.25	-7.32	-0.03
Debt / FCF Ratio	-0.05	-0.06	-0.05	-1.38	-12.29	-0.04
Net Debt / Equity Ratio	-1.06	-1.05	-1.04	-1.03	1.34	-0.83
Net Debt / EBITDA Ratio	-0.47	-0.63	-2.07	0.19	-2.40	0.82
Net Debt / FCF Ratio	1.51	2.14	2.85	1.04	-4.03	0.95
Quick Ratio	7.19	9.77	9.89	9.17	9.15	3.47
Current Ratio	7.41	9.87	10.15	9.30	16.93	3.80
Return on Equity (ROE)	-166.85%	-206.10%	-94.90%	-601.85%	-75.05%	-108.89%
Return on Assets (ROA)	174.80%	184.44%	61.39%	-99.68%	-18.54%	-79.85%
Return on Invested Capital (ROIC)	-4117.33%	-5145.51%	-2985.74%	-289.35%	-44.39%	-334.27%
Return on Capital Employed (ROCE)	196.78%	204.18%	68.01%	-106.98%	-20.22%	-101.18%
Earnings Yield	-8.27%	-8.23%	-1.74%	-37.93%	-9.65%	-24.91%
FCF Yield	-2.64%	-2.39%	-1.08%	-4.20%	-4.70%	-27.64%
Buyback Yield / Dilution	-4.04%	-4.06%	-15.96%	-220.50%	-46.78%	-89.45%
Total Shareholder Return	-4.04%	-4.06%	-15.96%	-220.50%	-46.78%	-89.45%

Updated May 1, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q